Where the benefits of renin-angiotensin-aldosterone system blockade for reduction of cardiovascular risk are similar for ACE inhibitors (ACEI) and ARBs are unknown. The answer to this question is of particular importance among diabetics, given the higher cardiovascular risk in this patient population. In this meta-analysis, the authors examined effect of ACEI and ARBs on the […]
Tag: ACE
PARAMOUNT offers hope for HF-PEF
Inhibition of the renin-angiotensin system with ACE-inhibitors or ARBs has failed to convincingly show that these drugs can improve survival and lower the risk of hospitalisation in patients with heart failure with preserved ejection fraction (HF-PEF). LCZ696 is a novel investigational combination angiotensin-receptor/neprilysin inhibitor (ARNI) consisting of valsartan and AHU-377 in a 1:1 mixture. AHU-377 […]